•  
  •  
 

Abstract

Background: Neutropenic fever is an oncologic emergency that requires quick intervention with anti-pseudomonal beta-lactam antibiotics, such as meropenem. Previous literature suggests that extended infusions of beta-lactam antibiotics may improve clinical outcomes. To date, there are 3 prior studies utilizing an extended infusion beta-lactam in this population; however, there is only one previous study investigating the use of extended infusion meropenem in patients with febrile neutropenia.

Objective: To describe the outcomes of eight patients receiving extended infusions of meropenem for the treatment of febrile neutropenia.

Methods: A retrospective chart review was completed including adult patients admitted to a community teaching hospital who received extended infusions of meropenem for febrile neutropenia.

Results: In this descriptive study, no patients receiving extended infusions of meropenem failed treatment, were readmitted for an infectious issue within 30 days, or endured inpatient mortality. Additionally, all eight patients defervesced within 48 hours, and four patients had a microbiologically documented infection. One patient incurred Clostridium difficile on day 2 of meropenem therapy.

Conclusions: Extended infusions of meropenem may be effective in the treatment of febrile neutropenia. Future studies comparing extended infusions to intermittent infusions of meropenem for febrile neutropenia are warranted.

Share

COinS